Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.

"Competing interests MF declares honoraria for advisory boards AstraZeneca, GSK, Incyclix, Lilly, MSD, Novartis, Takeda; consultancy for AstraZeneca, Eisai, Novartis; speaker’s fee and travel from AstraZeneca; speaker’s fees from GSK and ACT genomics; institutional research funding from AstraZeneca, BeiGene, Novartis. JL declares honoraria for advisory boards from AstraZeneca and GSK; financial support for conference attendance: AstraZeneca, GSK, and Novartis. SF declares financial/honoraria: honoraria for advisory board from Akesobio and MSD; financial support for conference attendance from Amgen; institutional research funding from Akesobio, Ambrax, Amgen, AstraZeneca, Aulos, BeiGene, Cullinian, Daiichi Sankyo, Edison Oncology, HaiHe Biopharma, MSD, Takeda, Vivace, and WMS. MW declares Institutional research support from Roche. TM declares honoraria for advisory boards from AstraZeneca, BMS, GSK, MSD, Novartis, Takeda. SBH declares honoraria for advisory boards from AstraZeneca, Eisai, GSK, MSD, Pfizer; speaker fees from Lilly; consultancy for Roche; education travel from Amgen, Novartis. KB declares honoraria for advisory boards/conference attendance from BMS, MSD, Novartis, Pierre Fabre; institutional research funding from BioGene, BMS, Eucure, Lilly, Merck, Regeneron. NM declares honoraria for advisory boards from AstraZeneca, Novartis, Pfizer, Gilead, Roche; financial support for conference from Amgen, Novartis. CF declares institutional research funding from MSD, the National Comprehensive Cancer Network (NCCN) Foundation, the NCCN Oncology Research Program, Pfizer, Taiho Oncology. AC declares institutional research funding from AnHeart, Astellas, Bayer, BeiGene, BMS, FibroGen, Genentech, Lilly, Merck Serono, MSD, Novartis, Roche, Servier, Takeda; advisory board or speaker fees from Amgen, Bayer, Merck Serono, Pierre Fabre, Roche, Servier in the last 5 years. RG and JW declare employment by BeiGene, Ltd. All other authors declare no competing interests."

"Funding This study was sponsored by BeiGene, Ltd. Open Access funding enabled and organized by CAUL and its Member Institutions."

"Clinical trial registration ClinicalTrial.gov: NCT02660034."